NASDAQ:ATHX - Athersys, Inc.
$1.39
 $0.00
0.00%
4:00PM EDT
2019-04-18
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ATHX     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 87   199. 07   233. 87  
42 stocks rank:  3. 44 K 1. 43 K 1. 06 K
# analyst opinions:  3. 00   14. 48   14. 09  

quick ratio:  3. 62   5. 29   1. 92  
current ratio:  3. 74   5. 64   2. 40  

target price low:  0. 90   84. 50   115. 74  
target price avg:  1. 91   110. 73   137. 39  
target price high:  2. 44   136. 41   157. 80  
1-yr high:  2. 79   114. 11   138. 85  
last close:  1. 39   87. 56   116. 78  
50-day avg:  1. 51   95. 43   123. 53  
200-day avg:  1. 79   94. 13   121. 20  
1-yr low:  1. 39   72. 67   98. 41  
volume:  389. 43 K 2. 43 M 4. 85 M
50-day avg volume:  491. 51 K 2. 72 M 4. 97 M
200-day avg volume:  564. 07 K 2. 90 M 4. 58 M

1-day return:  0. 00 % -0. 40 % 0. 07 %
this week return:  -3. 47 % -5. 72 % -4. 11 %
12-wk return:  -18. 71 % 1. 78 % -0. 04 %
52-wk return:  -23. 71 % 10. 81 % 14. 09 %

enterprise value (EV):  160. 39 M 51. 19 B 117. 96 B
market cap:  204. 11 M 43. 00 B 104. 52 B
EBITDA:  -24. 81 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -6. 47   4. 34   13. 27  
enterprise/revenue (EV/R):  6. 60   68. 16   13. 68  
total revenue:  24. 29 M 10. 61 B 38. 24 B
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -24. 28 M 2. 20 B 4. 21 B

shares outstanding:  146. 84 M 570. 91 M 1. 24 B
shares:  132. 71 M 571. 02 M 1. 23 B
shares short:  10. 70 M 9. 93 M 16. 79 M
shares short prior month:  10. 60 M 9. 96 M 16. 58 M
short ratio:  22. 21   5. 31   3. 30  
short % of float:  9. 30 % 5. 81 % 2. 61 %
total cash/share:  0. 35   11. 13   9. 30  
total cash:  51. 06 M 6. 70 B 7. 10 B
free cash flow:  -12. 38 M 3. 58 B 4. 74 B
operating cash flow:  -13. 35 M 4. 14 B 6. 32 B

book value:  0. 30   12. 76   26. 84  
price/book:  4. 65   3. 08   -1. 74  
gross profits:  -14. 37 M 8. 03 B 34. 77 B
operating margins:  -105. 64 % -721. 97 % -88. 82 %
EBITDA margins:  -102. 12 % 10. 94 % 22. 54 %
profit margins:  -99. 97 % 7. 81 % 10. 60 %
gross margins:  -59. 14 % 37. 02 % 55. 68 %

1-yr max volatility:  14. 39 % --- ---
1-yr mean volatility:  -0. 10 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 18   2. 39   4. 08  
forward EPS:  -0. 35   3. 97   7. 14  
P/E:  -7. 72   13. 59   22. 83  
forward P/E:  -4. 11   -20. 05   14. 49  
PE/G:  -0. 26   -1. 46   1. 68  
growth:  29. 30 % 126. 81 % 29. 29 %
earnings high:  -0. 06   1. 02   1. 63  
earnings avg:  -0. 08   0. 76   1. 51  
earnings low:  -0. 09   0. 47   1. 39  
revenue high:  3. 17 M 2. 68 B 10. 71 B
revenue avg:  1. 45 M 2. 59 B 10. 49 B
revenue low:  470. 00 K 2. 49 B 10. 25 B
return on assets:  -33. 65 % -2. 80 % 5. 29 %
return on equity:  -73. 04 % -18. 52 % 7. 38 %
revenue growth:  29. 30 % 92. 55 % 19. 15 %
revenue/share:  0. 18   13. 27   55. 24  

beta (1yr vs S&P500):  1. 20   1. 24   0. 93  
sharpe (1yr):  -0. 47   0. 29   0. 60  

held % insiders:  9. 99 % 6. 38 % 3. 38 %
held % institutions:  22. 77 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : ATHX
.    + 0.999 =         0.999 :: INITIAL WEIGHT
.   + 37.478 =        38.477 :: spline projection addition
.    x 1.432 =          55.1 :: industry recommendation factor
.    x 1.097 =        60.438 :: EV/R factor
.    x 0.997 =        60.234 :: return on assets factor
.    x 0.993 =        59.794 :: return on equity factor
.    x 2.358 =       141.025 :: revenue growth factor
.    x 2.663 =       375.541 :: current ratio factor
.    x 1.175 =       441.382 :: quick ratio factor
.    x 1.022 =        451.21 :: short ratio factor
.    x 2.046 =       923.395 :: price-to-book factor
.    x 2.031 =      1875.662 :: P/E weight
.    x 1.396 =      2617.796 :: PE/G factor
.    x 1.542 =      4036.326 :: beta factor
.    x 0.466 =      1880.568 :: sharpe factor
.    x 0.941 =      1768.913 :: target low factor
.    x 1.204 =      2129.509 :: target mean factor
.    x 1.087 =      2314.718 :: target high factor
.    x 1.312 =      3036.097 :: industry 2-weeks return factor
.    x 0.956 =       2903.05 :: "drift" penalty 1 days ago
.    x 0.939 =      2725.958 :: overall "drift" factor
.    x 0.856 =      2333.734 :: largest single-day jump factor
.    x 0.063 =       147.798 :: low price factor
.      x 1.0 =       147.774 :: factor hist industry gain for week 15
.   cubeRoot =         5.287 :: reduced to standardize
.   - 20.033 =         0.871 :: add/subtract for performance
.                      0.871 :: FINAL WEIGHT for NASDAQ:ATHX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org